Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

scPharmaceuticals, Inc.

http://www.scpharmaceuticals.com/

Latest From scPharmaceuticals, Inc.

ScPharmaceuticals Hopes To Win Payer Favor As It Prepares For Furoscix Resubmission

The company announced interim results of the FREEDOM-HF study showing nearly $18,000 in savings per heart failure patient.

Business Strategies Reimbursement

Keeping Track: J&J Amivantamab, Infectious Disease Agents From Iterum, VBI And Atox Submitted; Another Furoscix CRL

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker

Approvals Complete Response Letters

US FDA’s 2020 User Fee Calendar Still Holds Promise Of Merry Novel Approval Count

The FDA has almost 30 decision dates coming up before New Year’s Eve, including nearly a dozen novel agents.

Approvals Drug Review

Finance Watch: Investors Bet Billions On Big Biopharma Offerings

Public Company Edition: After an initial hit to valuations from COVID-19, massive amounts of money have been raised by drug developers, such as argenx with a $862.5m stock sale. However, only two IPOs launched in the US in May, including ADC with a $267m offering.

Financing Business Strategies
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Drug Delivery
UsernamePublicRestriction

Register